Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Natrogen Therapeutics International, Inc.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Natrogen Therapeutics International, Inc
ClinicalTrials.gov Identifier:
NCT01216280
First received: September 2, 2010
Last updated: June 24, 2011
Last verified: July 2010
  Purpose

This study is to evaluate the efficacy and tolerability of multiple oral doses of Natura-alpha capsule administered to patients with active ulcerative colitis. This will be a randomized, double-blind, placebo-controlled, parallel-design study. Up to 75 patients will complete this study (20 to 25 patients per treatment group) at approximately 10-12 clinical sites in the Unites States. Patients will be assigned at a 1:1:1 ratio to receive placebo, Natura-alpha 10 mg or Natura-alpha 20 mg, b.i.d. Replacement patients may be added, pending Sponsor approval, if it appears that less than 60 patients will complete the study.


Condition Intervention Phase
Ulcerative Colitis
Drug: placebo capsule
Drug: 10 mg Natura-alpha capsule and 10 mg placebo capsule
Drug: 2 x 10 mg Natura-alpha capsules
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Efficacy and Tolerability Study of Natura-Alpha in the Treatment of Patients With Active Ulcerative Colitis

Resource links provided by NLM:


Further study details as provided by Natrogen Therapeutics International, Inc:

Primary Outcome Measures:
  • Physician's Global Assessment(PGA) [ Time Frame: Day 28 after the treatment ] [ Designated as safety issue: No ]
    The primary efficacy endpoint will be the proportion of patients in all treatment groups with clinical response (improvement) at Day 28.


Secondary Outcome Measures:
  • Physician's Global Assessment (PGA) [ Time Frame: Day 28 after the treatment ] [ Designated as safety issue: No ]
    The proportion of patients in all treatment groups who achieve clinical remission at Day 28

  • Physician's Global Assessment (PGA) [ Time Frame: Day 7 ] [ Designated as safety issue: No ]
    The proportion of patients in all treatment groups who demonstrate clinical response

  • Physician's Global Assessment (PGA) [ Time Frame: 14 ] [ Designated as safety issue: No ]
    The proportion of patients in all treatment groups who demonstrate clinical response

  • Physician's Global Assessment (PGA) [ Time Frame: Day 28 ] [ Designated as safety issue: No ]
    The proportion of patients in all treatment groups who demonstrate clinical response who were previously corticosteroid, 5-aminosalicylic acid (5-ASA), immunosuppresant, TNF-alpha antibody therapy-refractory or intolerant

  • Safety [ Time Frame: Day 28 ] [ Designated as safety issue: Yes ]
    adverse events, changes in physical examination findings, vital signs, concomitant medications, and laboratory test results


Estimated Enrollment: 75
Study Start Date: July 2010
Estimated Study Completion Date: September 2011
Estimated Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: 2 x 10 mg placebo capsule
2 x 10 mg placebo capsules, administered orally with water, b.i.d.
Drug: placebo capsule
2 x 10 mg placebo capsules administered orally with water, b.i.d.
Other Name: Group 1
Experimental: 10mg Natura-alpha + 10 mg placebo
10 mg Natura-alpha capsule + 10 mg placebo capsule administered orally with water, b.i.d.
Drug: 10 mg Natura-alpha capsule and 10 mg placebo capsule
10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
Other Name: Group 2
Experimental: 2 x 10 mg Natura-alpha capsules
2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
Drug: 2 x 10 mg Natura-alpha capsules
2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
Other Name: Group 3

Detailed Description:

This will be a randomized, double-blind, placebo-controlled, parallel-design study. Eligible patients will have moderate to severe ulcerative colitis, defined as:

  • A Disease Activity Index (DAI) score of 6 to 10 (inclusive);
  • Endoscopic evidence of active ulcerative colitis (DAI mucosal appearance sub score of ≥2) as assessed by flexible sigmoidoscopy unless colonoscopy is clinically indicated;
  • Rectal bleeding (DAI sub score of ≥1);
  • Physician's Global Assessment (PGA) of moderate disease (DAI sub score ≥2). Patients will be randomized to receive placebo, 10 mg Natura-alpha or 20 mg Natura-alpha. Patients will self-administer their assigned dose orally for 28 consecutive days, twice per day (b.i.d) at approximately 8:00 am and 8:00 pm.

The effectiveness and safety of Natura-alpha will be evaluated at baseline, and after 7, 14 and 28 days of treatment. Additional follow-up measurements will take place 7 and 28 days post cessation of treatment (Day 35 and Day 56, respectively). Stool samples for fecal calprotectin (FC) tests and optional blood samples (15 ml) for cytokine tests will be collected and analyzed at sponsor-selected sites and lab for exploratory analyses to be performed at a later date.

Clinical response will be assessed by the Physician's Global Assessment (PGA) on the basis of sigmoidoscopy (Walkiewicz, Werlin et al. 2008) and mucosal appearance (DAI category). Sigmoidoscopy including histopathological examination to assess disease severity and changes in tissue inflammation will be conducted before and after treatment (Day 1, Day 28) by the same endoscopist at each site and read by one sponsor selected central pathologist. Truelove-Richards histological grading system will be applied for disease histological scoring (Pullan, Rhodes et al. 1994; Zhong, Huang et al. 2005; Liang and Ouyang 2008). Safety labs and adverse events (AEs) will be monitored for the duration of the study (including the 7 day follow up visit).

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Females must be of non-childbearing potential evidenced by being surgically sterile, postmenopausal for at least 12 months or be using acceptable contraception methods.
  • Subject is require to meet one of the following criteria:

    1. Newly diagnosed patients with moderate to severe ulcerative colitis evidenced by endoscopy and histopathology, who have never been medically treated for ulcerative colitis, or
    2. Patients with moderate to severe disease, as defined by a Disease Activity Index (DAI) score of 6-10 (inclusive) at the Baseline Visit (assessed at screening and verified at Day 1), with a negative evaluation of the terminal ileum within 3 years of the screening visit, or
    3. Patients with active ulcerative colitis who are refractory or intolerant to therapies of 5-ASA, steroids, immunosuppressants or anti-TNF-alpha.
  • Endoscopic evidence of active mucosal disease as assessed by flexible sigmoidoscopy, with a DAI mucosal appearance sub score ≥ 2.
  • DAI rectal bleeding sub score of ≥ 1.
  • Physician's Global Assessment (PGA) DAI sub score ≥ 2.
  • Ability to adhere to the study visit schedule and other protocol requirements.
  • Ability to provide voluntary written informed consent.
  • Adequate cardiac, renal and hepatic function as determined by site principal investigator and demonstrated by screening laboratory evaluations, and questionnaires, and physical examination results that are within normal limits.

Exclusion Criteria:

  • History of colonic or rectal surgery.
  • Pregnant or breast-feeding.
  • Diagnosis of diabetes, heart failure, unstable angina, hepatic cirrhosis, kidney failure, or any other unstable medical condition.
  • Known hypersensitivity to Natura alpha or any of the drug excipients.
  • Active and chronic infections.
  • Severe ulcerative colitis indicated by Disease Activity Index score > 10.
  • Patients with ulcerative proctitis (disease limited to less than 15 cm from the anal verge).
  • Use of any vaccine or any other immunostimulator within 4 weeks prior to the screening visit. .
  • Use of > 2.4 gm mesalamine or equivalent within 2 weeks prior to the screening visit.
  • Use of oral corticosteroids for more than 3 days during the two weeks prior to the screening visit.
  • Use of corticosteroid or 5-ASA enemas, foams, or suppositories at any time within two weeks prior to the screening visit. .
  • Use of TNF-alpha antibody or any other biologic therapy within 2 months prior to the screening visit. .
  • Use of immunosuppressive drugs at any time within four weeks prior to the screening visit. .
  • Use of oral or parenteral antibiotics at any time within two weeks prior to the screening visit.
  • Diagnosis of Crohn's disease.
  • Diagnosis of indeterminate colitis (inability to distinguish between ulcerative colitis and Crohn's disease).
  • Diagnosis of microscopic colitis (collagenous or lymphocytic colitis).
  • Diagnosis of ischemic, infectious (e.g., salmonella, shigella, etc.), or amebic colitis, or gonococcal proctitis.
  • Diagnosis of Clostridium difficile colitis.
  • History of positive serology to hepatitis B or C or human immunodeficiency virus (HIV) infection.
  • Active alcohol or drug abuse.
  • Known malignancy or history of malignancy that would reduce life expectancy.
  • Current smoker, or has been a smoker within 6 months prior to the screening visit.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01216280

Locations
United States, California
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
United States, Maryland
Chevy Chase Clinical Research
Chevy Chase, Maryland, United States, 20814
United States, Missouri
Kansas City Gastroenterology and Hepatology
Kansas City, Missouri, United States, 64131
United States, New Jersey
AGA Medical Research Associates, LLC
Egg Harbor, New Jersey, United States, 08324
United States, New York
Long Island Clinical Research Associates, LLP
Great Neck, New York, United States, 11021
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, United States, 12601
United States, Ohio
Consultants for Clinical Research
Cincinnati, Ohio, United States, 45219
Consultants for Clinical Research
Fairfield, Ohio, United States, 45014
United States, Tennessee
Nashville Medical Research Institute
Nashville, Tennessee, United States, 37205
United States, Wisconsin
Wisconsin Center for Advanced Research, LLC
Milwaukee, Wisconsin, United States, 53215
Sponsors and Collaborators
Natrogen Therapeutics International, Inc
Investigators
Study Director: Longgui Wang, MD Natrogen Therapeutics International, Inc
  More Information

No publications provided

Responsible Party: Longgui Wang/President, Natrogen Therapeutics International, Inc
ClinicalTrials.gov Identifier: NCT01216280     History of Changes
Other Study ID Numbers: NTI-2009-UC1, 70984
Study First Received: September 2, 2010
Last Updated: June 24, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by Natrogen Therapeutics International, Inc:
Natura-alpha
ulcerative colitis
cytokines
Th1
Th17

Additional relevant MeSH terms:
Colitis
Ulcer
Colitis, Ulcerative
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases

ClinicalTrials.gov processed this record on October 19, 2014